Pharmaceutical

Health Canada approves AstraZeneca-Merck’s prostate cancer therapy

AstraZeneca and Merck have received conditional approval from Health Canada for Lynparza (olaparib) combination to treat prostate cancer.

Jul 15, 2023 - 20:00
Health Canada approves AstraZeneca-Merck’s prostate cancer therapy
AstraZeneca and Merck have received conditional approval from Health Canada for Lynparza (olaparib) combination to treat prostate cancer.
Read the original article

Tags:

Previous Article

Gilead, CHAI and Penta to enhance HIV treatment for children

Next Article

Emmaus gains marketing authorisation for sickle cell treatment in Oman

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Innovation in immuno-oncology: Leading companies in microbiota restoration therapy

Innovation in immuno-oncology: Leading companies in mic...

May 8, 2023

Sotigalimab by Pyxis Oncology for Anaplastic Astrocytom...

Oct 27, 2023

STAT+: Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing

STAT+: Novartis is scolded by U.K. trade group for the ...

Jul 18, 2023